Antibiotic therapy and fat digestion and absorption in cystic fibrosis

• Authors: Aleksandra Lisowska , Andrzej Pogorzelski , Grzegorz Oracz , Wojciech Skorupa , Szczepan Cofta , Jarosław Szydłowski , Jerzy Socha , Jarosław Walkowiak
• Languages of publication: EN

Abstracts

EN

Antibiotic therapy in the cystic fibrosis (CF) mouse model has been shown to result in reduced bacterial load of the intestine and significant body mass gain. The effect was suggested to be linked to the improvement of intestinal digestion and absorption. Therefore, we aimed to assess the influence of routinely applied antibiotic therapy in CF patients on fat assimilation. Twenty-four CF patients aged 6 to 30 years entered the study. Inclusion criteria comprised confirmed exocrine pancreatic insufficiency and bronchopulmonary exacerbation demanding antibiotic therapy. Exclusion criteria comprised: antibiotic therapy six weeks prior to the test, liver cirrhosis, diabetes mellitus, oxygen dependency, the use of systemic corticosteroids. In all enrolled CF subjects, 13C-labelled mixed triglyceride breath test (13C MTG-BT) was performed to assess lipid digestion and absorption, before and after antibiotic therapy. Sixteen subjects were treated intravenously with ceftazidime and amikacin, eight patients orally with ciprofloxacin. Cumulative percentage dose recovery (CPDR) was considered to reflect digestion and absorption of lipids. The values are expressed as means (medians). The values of CPDR before and after antibiotic therapy did not differ in the whole studied group [4.6(3.3) % vs. 5.7(5.3) %, p = 0.100] as well as in the subgroup receiving them intravenously [4.6(3.2) % vs. 5.7(5.3) %, p = 0.327] or in that with oral drug administration [4.6(3.4) % vs. 5.7(5.4) %, p = 0.167]. In conclusion, antibiotic therapy applied routinely in the course of pulmonary exacerbation in CF patients does not seem to result in an improvement of fat digestion and absorption.

Keywords

EN

stable isotope breath test; malabsorption; antibiotic therapy; cystic fibrosis

• Journal: Acta Biochimica Polonica
• Year: 2011
• Volume: 58
• Issue: 3
• Pages: 345-347

Dates

published

2011

received

2010-12-10

revised

2011-05-13

accepted

2011-07-05

(unknown)

2011-07-07

Contributors

author

Aleksandra Lisowska

• 1st Chair of Pediatrics, Department of Pediatric Gastroenterology & Metabolism, Poznań University of Medical Sciences, Poznań, Poland

author

Andrzej Pogorzelski

• Department of Bronchology & Cystic Fibrosis, National Institute for Tuberculosis & Lung Diseases, Pediatric Branch, Rabka, Poland

author

Grzegorz Oracz

• Department of Pediatric Gastroenterology, Hepatology & Immunology, Child Memorial Health Institute, Warszawa, Poland

author

Wojciech Skorupa

• 1st Clinic of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Warszawa, Poland

author

Szczepan Cofta

• Department of Respiratory Medicine, Poznań University of Medical Sciences, Poznań, Poland

author

Jarosław Szydłowski

• Department of Pediatric Otorhinolaryngology, Poznań University of Medical Sciences, Poznań, Poland

author

Jerzy Socha

• Department of Pediatric Gastroenterology, Hepatology & Immunology, Child Memorial Health Institute, Warszawa, Poland

author

Jarosław Walkowiak

• 1st Chair of Pediatrics, Department of Pediatric Gastroenterology & Metabolism, Poznań University of Medical Sciences, Poznań, Poland

References

• Béghin L, Gottrand F, Michaud L, Loeuille GA, Wizla-Derambure N, Sardet A, Guimber D, Deschildre A, Turck D (2003) Impact of intravenous antibiotic therapy on total daily energy expenditure and physical activity in cystic fibrosis children with Pseudomonas aeruginosa pulmonary exacerbation. Pediatr Res 54: 756-761.
• Castro M, Diamanti A, Gambarara M, Bella S, Lucidi V, Papadatou B, Ferretti F, Rosati P, Rupi E (2002) Resting energy expenditure in young patients with cystic fibrosis receiving antibiotic therapy for acute respiratory exacerbations. Clin Nutr 21: 141-144.
• Hankard R, Munck A, Navarro J (2002) Nutrition and growth in cystic fibrosis. Horm Res 58 (Suppl 1): 16-20.
• Muhlebach MS, Stewart PW, Leigh MW, Noah TL (1999) Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 160: 186-191.
• Norkina O, Burnett DG, De Lisle RC (2004a) Bacterial overgrowth in cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 72: 6040-6049.
• Norkina O, Kaur S, Ziemer D, De Lisle RC (2004b) Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 286: G1032-G1041.
• Reilly JJ, Evans TJ, Wilkinson J, Paton JY (1999) Adequacy of clinical formulae for estimation of energy requirements in children with cystic fibrosis. Arch Dis Child 81: 120-124.
• Vic P, Ategbo S, Gottrand F, Launay V, Loeuille GA, Elian JC, Druon D, Farriaux JP, Turck D (1997) Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis. Arch Dis Child 76: 437-440.
• Walkowiak J (2004) Assessment of maldigestion in cystic fibrosis. J Pediatr 145: 285-287.
• Walkowiak J, Nousia-Arvanitakis S, Henker J, Stern M, Sinaasappel M, Dodge JA (2005) Indirect pancreatic function tests in children. J Pediatr Gastroenterol Nutr 40: 107-114.